These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9436408)

  • 21. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
    Kulua TK; Fedorova NV; Popovkina OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):45-50. PubMed ID: 22027607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 23. [Monoamine and monoamine enzyme abnormalities in childhood autism].
    Garnier C; Barthelemy C; Garreau B; Jouve J; Muh JP; Lelord G
    Encephale; 1983; 9(3):201-62. PubMed ID: 6317336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful management of pregnancy in a patient with Segawa disease: case report and literature review.
    Watanabe T; Matsubara S; Baba Y; Tanaka H; Suzuki T; Suzuki M
    J Obstet Gynaecol Res; 2009 Jun; 35(3):562-4. PubMed ID: 19527400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
    Walker SL; Fine A; Kryger MH
    Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopa responsive dystonia in a girl with vitiligo.
    Chaudhary N; Mani J; Rawat S; Mulye R; Shah P
    Indian Pediatr; 1998 Jul; 35(7):663-5. PubMed ID: 10216678
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of improvement in odor identification by levodopa in humans.
    Rösser N; Berger K; Vomhof P; Knecht S; Breitenstein C; Flöel A
    Physiol Behav; 2008 Mar; 93(4-5):1024-9. PubMed ID: 18294663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks.
    Serrano M; Pérez-Dueñas B; Ormazábal A; Artuch R; Campistol J; Torres RJ; García-Cazorla A
    Mov Disord; 2008 Jul; 23(9):1297-300. PubMed ID: 18528895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.
    Tse W; Frisina PG; Hälbig TD; Gracies JM; Liang L; Tarshish C; Lesser G; Neufeld R; Koller WC; Libow LS
    J Am Med Dir Assoc; 2008 Nov; 9(9):670-5. PubMed ID: 18992700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metabolism of serotonin in autism in children].
    Bursztejn C; Ferrari P; Dreux C; Braconnier A; Lancrenon S
    Encephale; 1988; 14(6):413-9. PubMed ID: 3068046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 32. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa.
    Asmus F; Horber V; Pohlenz J; Schwabe D; Zimprich A; Munz M; Schöning M; Gasser T
    Neurology; 2005 Jun; 64(11):1952-4. PubMed ID: 15955952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.
    Mohammadi MR; Yadegari N; Hassanzadeh E; Farokhnia M; Yekehtaz H; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):179-84. PubMed ID: 24201232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 36. Transport of dopamine and levodopa and their interaction in COS-7 cells heterologously expressing monoamine neurotransmitter transporters and in monoaminergic cell lines PC12 and SK-N-SH.
    Hashimoto W; Kitayama S; Kumagai K; Morioka N; Morita K; Dohi T
    Life Sci; 2005 Feb; 76(14):1603-12. PubMed ID: 15680169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
    Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
    Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder.
    Dean OM; Gray KM; Villagonzalo KA; Dodd S; Mohebbi M; Vick T; Tonge BJ; Berk M
    Aust N Z J Psychiatry; 2017 Mar; 51(3):241-249. PubMed ID: 27316706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design.
    Linday LA; Tsiouris JA; Cohen IL; Shindledecker R; DeCresce R
    J Neural Transm (Vienna); 2001; 108(5):593-611. PubMed ID: 11459079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.